Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The lutropin-choriogonadotropic hormone receptor (LHCGR) is a transmembrane protein belonging to the G protein-coupled receptor (GPCR) superfamily. It is primarily expressed in the ovary and testis and serves as a receptor for luteinizing hormone (LH) and chorionic gonadotropins (hCG). Upon ligand binding, it activates G proteins, stimulating adenylate cyclase and triggering downstream signaling pathways essential for reproductive function. Mutations in LHCGR can lead to various health conditions, including familial male-limited precocious puberty and infertility disorders.
Agonist or antagonist binding modulates downstream signaling via G proteins and adenylate cyclase activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lutropin-choriogonadotropic hormone receptor (LHCGR).